Abstract
Hepatitis B (HBV) drug resistance assay is important for guiding therapy after the development of virologic breakthrough for patients receiving nucleoside/-tide analog therapy. However, the existing genotyping tools are either costly or lack sensitivity to detect mixed genotypes, and an improved method of resistant mutation detection is needed. An assay protocol for clinical application using pyrosequencing method was developed, capable of detecting all known validated HBV polymerase gene mutations that impart resistance to lamivudine, adefovir, tenofovir, and entecavir. Sixty-eight serum samples with known HBV resistance genotypes, previously tested with either Sanger sequencing assay or commercial line probe assay, were used for validation. Where there were discrepancies between the two methods, clonal sequencing by Sanger's method was used for confirmation. The modified pyrosequencing method accurately identified all the cloned polymerase genotypes and was able to distinguish as little as 5% of the mutant populations. This assay can be performed on serum sample with HBV DNA as low as 13.5 IU/mL. The cost per test was less than existing commercial assay. HBV drug resistance pyrosequencing assay was accurate, more sensitive an...Continue Reading
References
Aug 15, 1998·Science·M RonaghiP Nyrén
Feb 3, 2000·Journal of Clinical Microbiology·L StuyverR Rossau
Jan 13, 2001·Genome Research·M Ronaghi
Oct 9, 2004·Journal of Clinical Microbiology·Anna LindströmJan Albert
Jun 29, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S LokUNKNOWN Hepatitis B Virus Drug Resistance Working Group
Nov 21, 2008·Journal of Hepatology·Bulent DegertekinAnna S Lok
Dec 5, 2008·Journal of Clinical Microbiology·Rosendo JardiMaria Buti
Dec 17, 2008·Journal of Virology·Mariacarmela SolmoneMaria Rosaria Capobianchi
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G Ghany, Edward C Doo
Sep 22, 2009·Methods in Molecular Biology·Jose Luis Royo, Jose Jorge Galán
Jan 13, 2010·Antimicrobial Agents and Chemotherapy·H G M NiestersE Sablon
Jun 21, 2011·Antiviral Therapy·Paula TumaUNKNOWN CoRIS Study Group
Jan 27, 2012·Journal of Oral Microbiology·José F SiqueiraIsabela N Rôças
Jun 8, 2012·BMC Microbiology·Francisco C A MelloSelma A Gomes
Jul 19, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ching-Lung Lai, Man-Fung Yuen
Sep 22, 2012·Journal of Experimental & Clinical Cancer Research : CR·Sylwia JancikMarian Hajduch
Jan 26, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Guan-Huei LeeSeng-Gee Lim
Sep 21, 2013·The Journal of General Virology·Sevim MeseEmel Bozkaya
Dec 5, 2013·Alimentary Pharmacology & Therapeutics·C PipiliG Papatheodoridis
Sep 1, 2015·PloS One·Shyamala IyerJames I Mullins